Compare CYTK & PRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CYTK | PRI |
|---|---|---|
| Founded | 1997 | 1927 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Life Insurance |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.0B | 8.3B |
| IPO Year | 2004 | N/A |
| Metric | CYTK | PRI |
|---|---|---|
| Price | $62.60 | $267.07 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 16 | 4 |
| Target Price | $82.38 | ★ $304.25 |
| AVG Volume (30 Days) | ★ 2.2M | 230.6K |
| Earning Date | 02-26-2026 | 02-10-2026 |
| Dividend Yield | N/A | ★ 1.56% |
| EPS Growth | N/A | ★ 65.97 |
| EPS | N/A | ★ 21.75 |
| Revenue | $87,211,000.00 | ★ $3,335,204,000.00 |
| Revenue This Year | $339.72 | $4.64 |
| Revenue Next Year | $79.08 | $4.73 |
| P/E Ratio | ★ N/A | $12.22 |
| Revenue Growth | ★ 2609.26 | 10.41 |
| 52 Week Low | $29.31 | $230.98 |
| 52 Week High | $70.98 | $298.75 |
| Indicator | CYTK | PRI |
|---|---|---|
| Relative Strength Index (RSI) | 47.75 | 57.39 |
| Support Level | $60.30 | $259.36 |
| Resistance Level | $65.08 | $270.43 |
| Average True Range (ATR) | 2.91 | 5.75 |
| MACD | -0.01 | 0.58 |
| Stochastic Oscillator | 45.74 | 69.91 |
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Primerica Inc is a provider of financial services to middle-income households in the United States and Canada. The company offers life insurance, mutual funds, annuities, and other financial products, distributed on behalf of third parties. Primerica has three main subsidiaries: Primerica Financial Services, a marketing company; Primerica Life Insurance Company, a principal life insurance underwriting entity; and PFS Investments, which offers investment and savings products, brokerage services, and registered investment advisory. It has three segments Term Life Insurance; Investment and Savings Products; and Corporate and Other Distributed Products. Geogriphically, it derives a majority of its revenue from the United States.